Pfizer gets FDA nod for new Rx antibiotic

A new Pfizer antibiotic, danofloxacin mesylate, has been approved by the Food and Drug Administration (FDA) for the treatment of bovine respiratory disease (BRD) in beef cattle.A180 enters the veterinary market for the treatment of BRD associated with Mannheimia (Pasteurella) haemolytica and Pasteurella multocida in beef cattle. The product is only available by prescription.The product has a unique four-day withdrawal period, and is administered as a concentrated low-volume subcutaneous injection (1.5 mL per 100 lbs. body weight).Pfizer says that BRD is one of the most prevalent and expensive cattle diseases, costing the United States beef cattle industry more than $1 billion annually in mortality, treatment costs, lost productivity and reduced carcass value.A180 underscores Pfizer s commitment to discovering and developing innovative antimicrobials that respond to the cattle industry needs, says Pedro Lichtinger, president of Pfizer Animal Health. In the years ahead, we are confident that our continuing research investment will offer further advances in supporting producers around the world.Rob DiMarzio, area president, U.S. operations, says Beef producers and veterinarians will find that A180 offers an effective new solution to BRD treatment consistent with their, and Pfizers, continuing support for the responsible use of antimicrobial products. Jim Gerardot, director and team leader of U.S. cattle pharmaceutical marketing, adds, Pfizer is very committed to the responsible use of antibiotics in livestock, therefore, A180 is only for prescription by a licensed veterinarian. Pfizer adds that administering the product according to the label directions and strict adherence to any withdrawal periods are especially important for end users.The product is only approved for use in the beef industry and is not intended for dairy production, or for calves to be processed for veal or human use, the company adds.

For fastest response call (800) 366-5288.